PI3K-mTOR in Cancer and Cancer Therapy
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-M…
Mehr
CHF 200.50
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Leyland-Jones, Brian (Hrsg.) / Dey, Nandini (Hrsg.)
- ISBN: 978-3-319-34211-5
- EAN: 9783319342115
- Produktnummer: 20076958
- Verlag: Humana Press
- Sprache: Englisch
- Erscheinungsjahr: 2016
- Plattform: PDF
- Masse: 5'600 KB
Über den Autor
Nandini Dey, M.S., Ph.D., is a Senior Scientist Head of Cancer Biology, Avera Cancer Institute Center for Precision Oncology. She is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. Dey has more than 20 years of experience in translational research and has authored or co-authored more than 80 publications.
2 weitere Werke von Pradip (Hrsg.) De:
Bewertungen
Anmelden